Browse FXYD1

Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane, sarcolemma Single-pass type I membrane protein Apical cell membrane Single-pass type I membrane protein Membrane, caveola Note=Detected in the apical cell membrane in brain. In myocytes, localizes to sarcolemma, t-tubules and intercalated disks.
Domain PF02038 ATP1G1/PLM/MAT8 family
Function

Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which transports Na(+) out of the cell and K(+) into the cell. Inhibits NKA activity in its unphosphorylated state and stimulates activity when phosphorylated. Reduces glutathionylation of the NKA beta-1 subunit ATP1B1, thus reversing glutathionylation-mediated inhibition of ATP1B1. Contributes to female sexual development by maintaining the excitability of neurons which secrete gonadotropin-releasing hormone.

> Gene Ontology
 
Biological Process GO:0002028 regulation of sodium ion transport
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006814 sodium ion transport
GO:0006820 anion transport
GO:0006821 chloride transport
GO:0006936 muscle contraction
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0010765 positive regulation of sodium ion transport
GO:0010959 regulation of metal ion transport
GO:0015672 monovalent inorganic cation transport
GO:0015698 inorganic anion transport
GO:0022898 regulation of transmembrane transporter activity
GO:0032409 regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035637 multicellular organismal signaling
GO:0035725 sodium ion transmembrane transport
GO:0036376 sodium ion export from cell
GO:0042391 regulation of membrane potential
GO:0043270 positive regulation of ion transport
GO:0044057 regulation of system process
GO:0060047 heart contraction
GO:0061337 cardiac conduction
GO:0071436 sodium ion export
GO:0086036 regulation of cardiac muscle cell membrane potential
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1902305 regulation of sodium ion transmembrane transport
GO:1902307 positive regulation of sodium ion transmembrane transport
GO:1902476 chloride transmembrane transport
GO:1903273 regulation of sodium ion export
GO:1903275 positive regulation of sodium ion export
GO:1903276 regulation of sodium ion export from cell
GO:1903278 positive regulation of sodium ion export from cell
GO:1903522 regulation of blood circulation
GO:1903779 regulation of cardiac conduction
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:2000649 regulation of sodium ion transmembrane transporter activity
Molecular Function GO:0005216 ion channel activity
GO:0005253 anion channel activity
GO:0005254 chloride channel activity
GO:0008509 anion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015108 chloride transmembrane transporter activity
GO:0015267 channel activity
GO:0016247 channel regulator activity
GO:0017080 sodium channel regulator activity
GO:0022803 passive transmembrane transporter activity
GO:0022838 substrate-specific channel activity
GO:0044325 ion channel binding
Cellular Component GO:0005890 sodium:potassium-exchanging ATPase complex
GO:0034702 ion channel complex
GO:0034707 chloride channel complex
GO:0042383 sarcolemma
GO:0090533 cation-transporting ATPase complex
GO:0098533 ATPase dependent transmembrane transport complex
GO:1902495 transmembrane transporter complex
GO:1904949 ATPase complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
Reactome R-HSA-5576891: Cardiac conduction
R-HSA-983712: Ion channel transport
R-HSA-5578775: Ion homeostasis
R-HSA-936837: Ion transport by P-type ATPases
R-HSA-397014: Muscle contraction
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FXYD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FXYD1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FXYD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.080.179
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6880.72
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.3850.285
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.0910.0767
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8830.435
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3510.313
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7950.21
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5920.526
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.2290.254
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5180.788
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2620.921
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7290.00179
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FXYD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FXYD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FXYD1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FXYD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FXYD1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FXYD1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFXYD1
NameFXYD domain containing ion transport regulator 1
Aliases PLM; phospholemman; FXYD domain-containing ion transport regulator 1
Chromosomal Location19q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FXYD1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.